 Dr. Richard Gregg
Chief Scientific Officer
Vitae Pharmaceuticals
 

 

 Dr. Gregg offers insight into the development of obesity drugs, and how co-morbidities factor into development, as well as how it impacts sites and CROs in Phase I through III trials.  
 
 

Challenges Sponsors Face in Diabetes Trials

Safety and Regulatory Aspects of Obesity Drugs

ePRO Use in Obesity and Hypertension Trials

Recorded Webcasts from the European Association for the Study of Diabetes Annual Meeting, October 2009

FDA Scientists Recognized at Diabetes Technology Meeting

 American Association of Diabetes Educators

American Diabetes Association, Professional Section

European Association for the Study of Diabetes

Clinical Trials for Type II Diabetes in Adults

Clinical Trials for Type II Diabetes in Children

Recent Study Pinpoints Weight Gain in Children Using Antipsychotics

International Association for the Study of Obesity

 European Association for the Study of Obesity

Clinical Trials for Metabolic Syndrome in Adults